Introduction
============

Atherosclerosis is one of the predominant causes of cardiovascular disease (CVD). More than 17.5 million people die each year because of CVDs.[@b1-ARYA-14-001] Due to the global growing rate of diabetes and obesity, it is expected that morbidity and mortality of CVD will increase.[@b2-ARYA-14-001] Therefore, it is of great significance to understand the precise mechanisms which are involved in atherosclerosis. Atherosclerosis is now regarded as a chronic inflammatory disorder of large and medium arteries.[@b3-ARYA-14-001] Cytokines are particularly significant in inflammatory processes,[@b4-ARYA-14-001] and many of them are believed to be complicated in atherogenesis.[@b5-ARYA-14-001] Several cytokines are detected in atherosclerotic plaque, on the other hand, all the cells involved in the disease can produce cytokines.[@b6-ARYA-14-001] These proteins are involved in initial stages of atherosclerosis, recruitment and activation of leukocytes, foam cell and fatty streak formation, development of complex lesions, plaque stability and rupture.[@b2-ARYA-14-001],[@b4-ARYA-14-001] It is noted that some cytokines have an anti-atherosclerotic effect.[@b2-ARYA-14-001] Several signaling pathways are involved in cytokines expression, among which nuclear factor ƙβ (NF-ƙβ) transcription factor is an important signaling pathway inducing the expression of some cytokines.[@b7-ARYA-14-001]

Salusin-β (with 20 amino acids) is a novel peptide which is discovered via bioinformatics analysis of a human full-length cDNA library.[@b8-ARYA-14-001] This protein is synthesized from pre-pro-salusin which is expressed at a great level in human vascular smooth muscle cells (VSMCs) and endothelial cells.[@b8-ARYA-14-001] It is indicated that salusin-β is released greatly from cell lines such as THP-1 (a human monocytic cell line) and U937 (a model cell line for the study of behavior and differentiation of monocytes), at the time of stimulation to be differentiated into macrophages.[@b9-ARYA-14-001] Several data indicated that this protein has a pathophysiological role in atherosclerosis via overexpression of acyl-CoA, cholesterol acyltransferase-1 (ACAT-1) and increase in macrophage foam cell formation (an important step in atherosclerosis),[@b10-ARYA-14-001] stimulation of the proliferation of VSMCs and fibroblasts and induction of the expression of c-myc, c-fos.[@b8-ARYA-14-001] Also in vivo and in vitro studies have shown that Salusin-β accelerates inflammatory responses in vascular endothelial cells.[@b11-ARYA-14-001]

As noted, salusin-β contributes to the pathogenesis of atherosclerosis, but little is known about the effect of this protein on pro- and anti-inflammatory cytokines expression. We aimed to assess the effect of salusin-β on interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 18 (IL-18) (as inflammatory cytokines) and interleukin 1Ra (IL-1Ra) (as anti-inflammatory cytokines) levels in human umbilical vein endothelial cells (HUVECs). Further, we assessed the probable involvement of NF-ƙβ signaling pathway in salusin-β effect on cytokines.

Materials and Methods
=====================

This study was performed at Isfahan University of Medical Sciences, Iran, (grant number 394287) and Hamadan University of Medical Sciences, Iran, (2015-2016). Salusin-β was provided by PeptaNova (Cat No: 4417-s, Japan), and E)-3-(4-methylphenyl sulfonyl)-2-propenenitrile (Bay 11-7082) was supplied from Cayman chemical (CAY10010266, USA). All other substances were acquired with best attainable purity grade.

HUVEC (ATCC® CRL-1730) was purchased from Pasteur Institute, Tehran, Iran. The cells were cultured in cell culture treated flasks and grown in HUVEC completed medium, containing Dulbecco\'s modified Eagle medium: nutrient mixture F-12 (DMEM/F12), endothelial cell growth factor (ECGF), non-essential amino acid (NEAA), Heparin, Insulin, Nap and 10% fetal bovine serum, in a humidified 5% CO2 incubator at 37 °C. The cells were pretreated with or without various concentrations of salusin-β (3, 10, 30, 90 nM) for 6 and 12 hours. Also, HUVECs were treated in the presence or absence of Bay 11-7082 (3 and 10 µM) as NF-ƙβ signaling pathway inhibitor.

The cell viability was assessed by the reduction of MTT to its insoluble formazan.[@b12-ARYA-14-001] HUVECs (5000 cells/well) were seeded in 96-well microplates. After overnight incubation, the cells were treated with different concentrations of salusin-β (1, 3, 10, 30, 90 and 180 nM) for 24 hours. Afterward, the cells were incubated at 37 °C with 15 µl of MTT (5 mg/ml) in phosphate- buffered saline for 4 hours. Then, the medium was removed and 150 µl of dimethyl sulfoxide (DMSO) was added and the absorbance at 570 nm and 630 nm was measured by an enzyme-linked immunosorbent assay (ELISA) reader.

After RNA extraction by TRIzol® Reagent (Thermo Fisher Scientific, Cat No: 15596-026, USA) according to manufacturer\'s protocol, RNA concentration and purity were determined by microspectrophotometer (A & E Lab, UK). RNA was converted to first- strand cDNA by Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Cat No: K-1622, USA). The mRNA expression of IL-6, IL-8, IL-18 and IL-1Ra were measured by real-time polymerase chain reaction (PCR) system (BioRAD CFX 96) and Syber® Premix Ex TaqTMII (Takara, Cat.RR820L, Japan). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control gene. Real-time PCR data were quantified by 2-ΔΔCT method,[@b13-ARYA-14-001] it should note that the PCR efficiency of the target gene was similar to the internal control gene. All samples and no template controls were examined in duplicates. All amplicons ([Table 1](#t1-ARYA-14-001){ref-type="table"}) were confirmed by sequencing (sequencing service-Bioneer, South Korea).

The IL-6 level was determined by a human IL-6 ELISA kit, Affymetrix eBioscience (catalog No: 88-7066, USA) sensitivity ˂ 2 pg/ml. The protein level of IL-8 was measured by Human IL-8 Elisa kit Affymetrix eBioscience (catalog No: 88-8086, USA), sensitivity 2 pg/ml. These ELISA kits were specifically engineered for accurate and precise measurement protein levels of IL-6 and IL-8, respectively. The protein level of IL-18 was quantified with Human IL-18 Elisa kit, Boster Bio (catalog No: EK0864, USA), with a sensitivity ˂ 1 pg/ml. The protein level of IL-1Ra was determined by human IL-1Ra Elisa kit, Boster Bio (catalog No: EK0782, USA) with a sensitivity less than 2 pg/ml.

These ELISA kits were specific for natural and recombinant IL-18 and IL-1Ra, respectively. The procedures were done according to manufacturer's instructions. All cytokine level was measured in cell culture supernatant treated with salusin-β after 6 and 12-hour treatments. All samples were analyzed in duplicates.

Data were presented as the mean ± standard deviation (SD). Statistical analyses were performed using one-way analysis of variance (ANOVA) test. Bonferroni post-hoc test was done to access statistical differences between groups. The normality test was controlled by Kolmogorov-Smirnov test. The results supported normality of our variables. P ˂ 0.050 was considered as statistically significant. The statistical analyses were accomplished by SPSS software (version 24, IBM Corporation, Armonk, NY, USA).

Results
=======

***The effect of salusin-β on HUVECs:***HUVECs viability was assessed by the MTT assay. The results indicated that salusin-β had no cytotoxic effect in HUVECs in the concentration range of 1-180 nM.

***The effect of salusin-β on mRNA expression of IL-6, IL-8, IL-18 and IL-1Ra:*** To assess whether salusin-β could exert an inflammatory effect on endothelial cells via modulating cytokines expression, mRNA expression of pro- and anti- inflammatory cytokines were determined. The results were reported base on Bonferroni post-hoc test. The mRNA expression of IL-6 was increased by salusin-β at 30 nM (2.86 ± 0.20, P ˂ 0.001) and 90 nM (1.82 ± 0.02, P = 0.007) for 6-hour treatment, and 90 nM (2.17 ± 0.20, P = 0.013) for 12-hour treatment. Also, we observed that mRNA expression of IL-8 was increased at 10 nM (1.92 ± 0.08, P = 0.021), 30 nM (2.68 ± 0.19, P = 0.001) and 90 nM (5.44 ± 0.24, P ˂ 0.001) for 6-hour treatment, and at 90 nM (2.00 ± 0.09, P = 0.002) for 12-hour treatment. The mRNA expression of IL-18 was increased at 30 nM (2.55 ± 0.01, P = 0.014) and 90 nM (3.17 ± 0.40, P = 0.003) for 6-hour treatment, and at 90 nM (1.70 ± 0.11, P = 0.012) for 12-hour treatment.

Salusin-β reduced mRNA expression of IL-1Ra at 10 nM (0.41 ± 0.08, P = 0.005), 30 nM (0.57 ± 0.11, P = 0.021) and 90 nM (0.60 ± 0.03, P = 0.026) for 6-hour treatment. The mRNA expression of IL-1Ra was decreased at 10 nM (0.22 ± 0.03, P = 0.006), 30 nM (0.26 ± 0.01, P = 0.008) and 90 nM (0.37 ± 0.04, P = 0.017) for 12-hour treatment ([Table2](#t2-ARYA-14-001){ref-type="table"}).

***The effect of salusin-β on protein level of IL-6, IL-8, IL-18 and IL-1Ra:***In line with the changes in cytokines mRNA, we observed that protein level of pre- and anti-inflammatory cytokines were changed. The production of IL-6 was increased at 90 nM for 6-hour and 12-hour treatments (82.62 ± 4.81 pg/ml vs. 42.89 ± 4.11 pg/ml in untreated cells, P = 0.004 and 118.06 ± 15.02 pg/ml vs. 65.92 ± 5.21 pg/ml in untreated cells, P = 0.040, respectively) ([Figures 1](#f1-ARYA-14-001){ref-type="fig"}A and [1](#f1-ARYA-14-001){ref-type="fig"}B). The results indicated that salusin-β at 90 nM increased protein level of IL-8 (238.82 ± 3.98 pg/ml vs. 178.10 ± 1.80 in untreated cells) for 6-hour treatment (P = 0.036); however, 12-hour treatment had no effect on protein level of IL-8 (dose 3 nM: P = 0.074, dose 10 nM: P = 0.841, dose 30 nM: P = 0.188, and dose 90 nM: P = 0.072) ([Figure 2](#f2-ARYA-14-001){ref-type="fig"}A and [2](#f2-ARYA-14-001){ref-type="fig"}B). Treatment of HUVECs with different doses of salusin-β increased protein level of IL-18 at 90 nM (84.82 ± 0.76 pg/ml vs. 35.49 ± 1.41 pg/ml untreated cells) (P ˂ 0.001) for 12-hour treatment. It was noted that 6-hour treatment had no effect on protein level of IL-18 (dose 3 nM: P \> 0.999, dose 10 nM: P \> 0.999, dose 30 nM: P = 0.330, dose 90 nM: P = 0.055) ([Figures 3](#f3-ARYA-14-001){ref-type="fig"}A and [3](#f3-ARYA-14-001){ref-type="fig"}B). The protein level of IL-1Ra was decreased at 30 and 90 nM (7.33 ± 1.20 pg/ml and 5.82 ± 0.76 pg/ml, respectively vs. 16.52 ± 0.70 pg/ml in untreated cells) for 12-hour treatment (P = 0.020 and P = 0.010, respectively). Salusin- β at 6-hour treatment had no effect on IL-1Ra protein level, (dose 3 nM: P \> 0.999, dose 10 nM: P \> 0.999, dose 30 nM: P \> 0.999, dose 90 nM: P = 0.594) ([Figure 4](#f4-ARYA-14-001){ref-type="fig"}A and [4](#f4-ARYA-14-001){ref-type="fig"}B).

***The role of NF-kβ signaling pathway in Salusin-β treatment:***To better understand the mechanisms of salusin-β-triggered cytokine expression, we measured mRNA expression of cytokines in the pretreatment of Bay 11-7082 (3, 10 µM) and salusin-β treatment. The results indicated that Bay 11-7082 (10 µM) can suppress the up-regulatory effect of salusin-β on mRNA expression of IL-6, 0.67 ± 0.11 (P = 0.002), [Figure 5](#f5-ARYA-14-001){ref-type="fig"}A. Also, Bay 11-7082 (10 µM) inhibited the up-regulatory effect of salusin-β on mRNA expression of IL-18 (0.95 ± 0.09) (P = 0.023) ([Figure 5](#f5-ARYA-14-001){ref-type="fig"}B).

Also, we observed that Bay 11-7082 (3 and 10 µM) inhibits IL-8 mRNA expression induced by salusin-β (0.37 ± 0.09 and 0.45 ± 0.06, respectively) (P ˂ 0.001) ([Figure 5](#f5-ARYA-14-001){ref-type="fig"}C). This inhibitor had no effect on the down-regulatory effect of salusin-β on IL-1Ra mRNA expression, data not indicated.

Discussion
==========

Endothelial cells have a fundamental function in the inflammatory response. These cells can synthesize various pro-inflammatory cytokines in response to different stimuli.[@b14-ARYA-14-001] The present study, for the first time, demonstrated that salusin-β can increase mRNA and protein level of pro-inflammatory cytokines including IL-6, IL-8 and IL-18 and decrease mRNA and protein level of IL-1Ra in HUVECs. Several studies confirmed that salusin-β has a pro-atherogenic effect,[@b15-ARYA-14-001],[@b16-ARYA-14-001] considering the prominent role of cytokines in key pathogenic events in atherosclerosis, it is worth to recognize the relationship between salusin-β and cytokines.

IL-8 is an atherogenic chemokine. The high level of this protein has been reported in the arterial atherosclerotic wall, atherosclerotic plaques and macrophages.[@b17-ARYA-14-001] IL-8 is involved in firm adhesion of monocytes to vascular endothelium under flow condition, a crucial step in atherosclerosis initiation.[@b18-ARYA-14-001] Also, IL-8 can promote monocytes and neutrophils activation.[@b19-ARYA-14-001] Because of specific biochemical properties of IL-8, this cytokine is a perfect choice for sites of inflammation.[@b20-ARYA-14-001] IL-8 is a mitogenic and chemotactic factor for VSMCs, which up-regulates mRNA expression and production of matrix metallopeptidase 2 (MMP2) and matrix metallopeptidase 9 (MMP9) in endothelial cells.[@b21-ARYA-14-001] It also inhibited tissue inhibitor of metalloproteinase 1 (TIMP-1) expression which leads to an imbalance between matrix metalloproteinase and TIMP-1; consequently, resulting in atherosclerotic plaque rupture and thrombosis.[@b22-ARYA-14-001] Therefore, IL-8 can accelerate the initiation, progression and plaque destabilization.

Very recent studies revealed that salusin-β can elevate migration and intimal hyperplasia of VSMCs via reactive oxygen species (ROS)/NF-ƙβ/MMP-9 pathway.[@b23-ARYA-14-001]

Our results indicated that salusin-β increases mRNA and protein level of IL-8 in HUVECs. As noted above, salusin-β accelerates oxidative stress leading to activation of NF-ƙβ signaling pathway in endothelial cells.[@b11-ARYA-14-001] Furthermore, salusin-β induces mRNA expression of IL-1β.[@b11-ARYA-14-001] It is well known that these factors are involved in IL-8 expression.[@b24-ARYA-14-001],[@b25-ARYA-14-001]

IL-18 is an important player in atherosclerotic processes. This cytokine is highly expressed in macrophages, endothelial cells and smooth muscle cells (SMCs) of atherosclerotic lesions. Recombinant IL-18 accelerates atherogenesis and increases cytokines level such as IL-1β, IL-8, IL-6,[@b26-ARYA-14-001]-[@b28-ARYA-14-001] also intensify adhesion molecules expression such as vascular cell adhesion protein 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) in endothelial cells and fibroblasts.[@b29-ARYA-14-001] Thus, IL-18 results in endothelial dysfunction.[@b28-ARYA-14-001] IL-18 has a close association with interferon gamma (IFN-γ) induction and it is proposed that pro-atherogenic effect of IL-18 is mediated by this cytokine. IFN-γ has a key role in atherosclerosis especially in foam cell formation via up-regulation of scavenger receptor for phosphatidylserine and oxidized lipoprotein (SR-PSOX).[@b30-ARYA-14-001] IFN-γ inhibits collagen synthesis by SMCs, thereby can modulate collagen content of atherosclerotic plaques.[@b31-ARYA-14-001] IL-18 deficiency is associated with decreased recruitment of macrophages.[@b2-ARYA-14-001] Apoptosis of endothelial cells and acceleration of migration and proliferation of SMCs is mediated by IL-18.[@b32-ARYA-14-001],[@b33-ARYA-14-001] In vivo studies indicated that endogenous inhibitor of IL-18 impeded fatty streak development in the thoracic aorta and has slowing effect on progression of advanced atherosclerotic plaque.[@b34-ARYA-14-001]

IL-18 is a part of IL-1 superfamily; therefore, this cytokine has structural and functional similarity with IL-1β. It also has the identical signaling cascade in common with IL-1β.[@b35-ARYA-14-001] Salusin-β increased mRNA expression of IL-1β and this study showed that salusin-β increased mRNA and protein level of IL-18 in HUVECs, suggesting a crosstalk between salusin-β, IL-1β and IL-18.

IL-6 is expressed in human atherosclerotic plaque and increases inflammatory cascade.[@b36-ARYA-14-001],[@b37-ARYA-14-001] IL-6 is involved in the expression of acute phase proteins in SMCs, also in migration and differentiation of activated macrophages.[@b38-ARYA-14-001] IL-6 accelerates the proliferation of VSMCs and enhances the permeability of endothelial cells.[@b14-ARYA-14-001] These events are included in onset and development of atherosclerosis. Animal studies have shown that recombinant IL-6 caused atherosclerotic lesion development.[@b39-ARYA-14-001] IL-6 is a pro-coagulant cytokine,36 which can activate the tissue factor production.[@b40-ARYA-14-001] Therefore, IL-6 has a role in plaque stability and rupture. It is demonstrated that endothelial cells can express ICAM-1 when are exposed to several inflammatory cytokines such as IL-6.39 The studies indicated that salusin-β can increase mRNA level of ICAM-1. This study revealed that salusin-β increased mRNA and protein level of IL-6 in HUVECs. In line with our results, in vivo and in vitro studies indicated that salusin-β increased protein level of IL-6; however, these studies did not measure mRNA expression of IL-6.[@b41-ARYA-14-001]

IL-1 is an influential pro-inflammatory cytokine in vascular hemostasis. This cytokine induces the production of some cytokines and chemokines,[@b42-ARYA-14-001] and stimulates adhesion molecule expression which accelerates monocyte recruitment and permeation into the arterial wall.[@b43-ARYA-14-001] Also, IL-1 participates in the development of tissue damage via inducing cell proliferation and matrix metalloproteinases release.[@b43-ARYA-14-001],[@b44-ARYA-14-001]

IL-1Ra is a negative regulator of IL-1 signaling and has a role in maintaining vascular hemostasis.[@b44-ARYA-14-001],[@b45-ARYA-14-001] It is proved that treatment of apolipoprotein E (ApoE) / mice with recombinant IL-1Ra is an impressive therapy for atherosclerosis.[@b45-ARYA-14-001] Several lines of evidence indicated that IL-1Ra has an anti-atherosclerotic effect.[@b5-ARYA-14-001],[@b46-ARYA-14-001] Animal studies indicated that lack of IL-1β causes less atherosclerotic lesions development;42 On the other hand, partial deficiency of IL-1Ra changes the composition of atherosclerotic plaques with a higher level of membrane cofactor protein 1 (MCP-1), ICAM-1 and VCAM-1 mRNA and accelerates vascular inflammation.[@b42-ARYA-14-001] Salusin-β increased mRNA level of MCP-1, ICAM-1, VCAM-1 and IL-1β in HUVECs.[@b11-ARYA-14-001] Our results indicated that salusin-β decreased mRNA/ protein level of IL-1Ra in HUVECs. Because the balance between IL-1 and IL-1Ra may have a role in atherogenesis development,42 we suggested the other role for salusin-β via disturbance in IL-1 and IL-1Ra equilibrium.

NF-ƙβ is an important transcription factor in inflammatory processes.[@b47-ARYA-14-001] This transcriptional factor regulates transcriptions of several genes with a well-known function in atherosclerosis including cytokines, chemokines and adhesion molecules.[@b48-ARYA-14-001] The promoters of IL-6 and IL-8 genes have functional NF-ƙβ binding sites which have been proven to be essential for the transcriptional activation of these genes.[@b14-ARYA-14-001] Also, several studies confirmed the involvement of NF-ƙβ signaling pathway in IL-18 expression.[@b48-ARYA-14-001]-[@b50-ARYA-14-001] The studies demonstrated that salusin-β accelerated vascular inflammatory responses via NF-ƙβ signaling pathway.[@b11-ARYA-14-001] We found that this complex protein involved in the up-regulatory effect of salusin-β on pro-inflammatory cytokines.

This study was performed with some limitations. We only studied mRNA expression of cytokines in the involvement of NF-ƙβ signaling pathway and further studies are necessary to confirm these results. Also, we could not study another cytokine-associated signaling pathway. Regarding no involvement of NF-ƙβ signaling pathway on the down-regulatory effect of salusin-β on IL-1Ra, it seems that the other cytokine-associated signaling pathways must be investigated.

Conclusion
==========

Primary prevention of atherosclerosis, which is important for the management of atherosclerotic CVD, requires comprehensive assessment and modification of molecular cardiovascular risk factors. Cytokines are a central player in atherosclerotic processes. To the best of our knowledge, this is the first study to indicate the association of salusin-β with pro- and anti-inflammatory cytokines. This work indicated that salusin-β increased mRNA/protein level of IL-6, IL-8 and IL-18 as pro-inflammatory cytokines and decreased mRNA/protein level of IL-1Ra as an anti-inflammatory cytokine in HUVECs. The previous studies demonstrated the accelerator effect of salusin-β on vascular inflammation. It seems that salusin-β may participate in a cascade pathway in vascular inflammation ([Figure 6](#f6-ARYA-14-001){ref-type="fig"}). Our novel results can help to open up a new vista into the potential use of salusin-β as a therapeutic target for the prevention of atherosclerosis. Prospective studies to determine the mechanisms latent down-regulatory effect of salusin-β on IL-1Ra and in vivo researches are recommended.
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![The effect of salusin-β on protein level of interleukin 6 (IL-6) at different time points and concentrations. Salusin-β (90nM) increased IL-6 protein level at 6-hour (A) and 12-hour (B) treatment; \* P \< 0.050, \*\* P \< 0.010 IL-6: Interleukin 6](ARYA-14-001f1){#f1-ARYA-14-001}

![The effect of salusin-β on protein level of interleukin 8 (IL-8). Salusin-β (90 nM) increased protein level of IL-8 at 6-hour treatment (A), and had no effect at 12-hour (B) treatment; \* P \< 0.050 IL-8: Interleukin 8](ARYA-14-001f2){#f2-ARYA-14-001}

![The effect of salusin-β on protein level of interleukin 18 (IL-18) at different time points and concentrations. Salusin- β (90nM) increased IL-18 protein level at 12-hour treatment (B), with no effect at 6-hour treatment (A); \*\* P \< 0.001 IL-18: Interleukin 18](ARYA-14-001f3){#f3-ARYA-14-001}

![The effect of salusin-β on protein level of interleukin 1Ra (IL-1Ra) at different time points and concentrations. Salusin-β (90 and 180 nM) reduced protein level of IL-1Ra at 12-hour treatment (B), without any effect at 6-hour treatment (A); \* P \< 0.050, \*\*P \< 0.010 IL-1Ra: Interleukin 1 Ra](ARYA-14-001f4){#f4-ARYA-14-001}

![The involvement of nuclear factor ƙβ (NF-ƙβ) signaling pathway in up-regulating effect of salusin-β on interleukin 6 (IL-6) (A), interleukin 18 (IL-18) (B), and interleukin 8 (IL-8) (C) mRNA expression; \* P \< 0.050, \*\* P \< 0.010 IL-6: Interleukin 6; IL-18: Interleukin 18; IL-8: Interleukin 8; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase](ARYA-14-001f5){#f5-ARYA-14-001}

![Salusin-β intensifies vascular inflammation via several mechanisms. It increases oxidative stress, adhesion molecules and inflammatory cytokine expression. On the other hand, salusin-β decreases antiinflammatory cytokine level](ARYA-14-001f6){#f6-ARYA-14-001}

###### 

Polymerase chain reaction (PCR) primers and the PCR product size

  Gene     Accession number             Sequence                      PCR product (bp)
  -------- ---------------------------- ----------------------------- ------------------
  GAPDH    NM_002046.5 (Variant 1)      F: AAGGCTGTGGGCAAGGTCATC      248
           NM_001256799.2 (Variant 2)                                 
           NM_001289745.1 (Variant 3)   R: GCGTCAAAGGTGGAGGAGTGG      
           NM_001289746.1 (Variant 4)                                 
  IL-1Ra   NM_173842.2                  F: GCAAGCCTTCAGAATCTGGGA T    185
           NM_173843.2                                                
           NM_173841.2                  R: ACTTGACACAGGACAGGC ACA T   
           NM_000577.4                                                
  IL-6     NM_000600.3                  F: CTGGATTCAATGAGGAGAC        206
                                        R: ATTTGTGGTTGGGTCAGG         
  IL-8     NM_000584                    F: AACACAGAAATTATTGTAAAG      149
                                        R: CACTGATTCTTGGATACC         
  IL-18    NM_001562.3                  F: AACCTCAGACCTTCCAG          292
           NM_001243211.1               R GCATTATCTCTACAGTCAG         

GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; IL-1Ra: Interleukin 1Ra; IL-6: Interleukin 6; IL-8: Interleukin 8; IL-18: Interleukin 18; F: Forward; R: Reverse; bp: Base pair; NM: mRNA accession number; PCR: Polymerase chain reaction

###### 

The expression ratio of each target gene normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in treated cells with different doses of salusin-β compared to untreated cells

  Target Gene   Salusin-β                                                                                                                                                                                                                                                                                                                                   
  ------------- ------------- ------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- -----------------------------------------------------------
  IL-6          0.89 ± 0.04   1.20 ± 0.20   1.31 ± 0.02                                                 0.91 ± 0.18                                                 2.86 ± 0.20[\*\*\*](#tfn5-ARYA-14-001){ref-type="table-fn"}   1.26 ± 0.04                                                 1.82 ± 0.02[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}     2.17 ± 0.20[\*](#tfn3-ARYA-14-001){ref-type="table-fn"}
  IL-8          1.60 ± 0.09   1.26 ± 0.13   1.92 ± 0.08[\*](#tfn3-ARYA-14-001){ref-type="table-fn"}     0.71 ± 0.11                                                 2.68 ± 0.19[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}     1.03 ± 0.02                                                 5.44 ± 0.24[\*\*\*](#tfn5-ARYA-14-001){ref-type="table-fn"}   2.00 ± 0.09[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}
  IL-18         1.26 ± 0.20   1.50 ± 0.12   1.97 ± 0.11                                                 0.96 ± 0.13                                                 2.55 ± 0.01[\*](#tfn3-ARYA-14-001){ref-type="table-fn"}       0.94 ± 0.06                                                 3.17 ± 0.40[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}     1.70 ± 0.11[\*](#tfn3-ARYA-14-001){ref-type="table-fn"}
  IL-1Ra        0.58 ± 0.05   0.61 ± 0.15   0.41 ± 0.08[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}   0.22 ± 0.03[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}   0.57 ± 0.11[\*](#tfn3-ARYA-14-001){ref-type="table-fn"}       0.26 ± 0.01[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}   0.60 ± 0.03[\*](#tfn3-ARYA-14-001){ref-type="table-fn"}       0.37 ± 0.04[\*\*](#tfn4-ARYA-14-001){ref-type="table-fn"}

Data are shown as mean ± standard deviation (SD); One-way analysis of variance and Bonferroni post-hoc tests are used;

P \< 0.050

P \< 0.010

P \< 0.001

IL-6: Interleukin 6; IL-8: Interleukin 8; IL-18: Interleukin 18; IL-1Ra: Interleukin 1Ra
